A329 lack of an RCT makes formal technology assessment vs. alternative treatment (e.g., best supportive care [BSC]) challenging. In such instances, naïve indirect comparison based on historical controls is typically employed. We present a method for estimating outcomes for untreated patients when appropriate historical controls are not available, by using data from non-responders in an uncontrolled trial. METHODS: Ofatumumab was licensed for fl udarabine-and alemtuzumab-refractory chronic lymphocytic leukaemia (FA-Ref CLL) based on results of an uncontrolled trial (Hx-CD20-406). To evaluate the cost-effectiveness of ofatumumab vs. BSC from the UK National Health Service perspective, a partitioned survival analysis model was developed. Progression free survival (PFS) and overall survival (OS) for ofatumumab were estimated by fi tting Weibull survival functions to failure time data for all FA-Ref patients in Hx-CD20-406. Following a literature search, no suitable historical control representing BSC could be identifi ed; therefore hazard ratios for PFS and OS for BSC vs. ofatumumab were estimated by fi tting Cox regression models to data for non-responders vs. all FA-Ref patients. Costs and utilities were taken from both published and unpublished sources. RESULTS: BSC patients (approximated by non-responders) were estimated to achieve 4.7 months PFS, 11.3 months OS, 0.50 QALYs, and expected lifetime costs of £4,876. Ofatumumab patients were estimated to reach 6.5 months PFS, 17.9 months OS, 0.77 QALYs, with expected lifetime costs of £43,828. CONCLUSIONS: The novel approach presented permits a practical alternative for estimating cost-effectiveness when neither an RCT nor appropriate historical control can be identifi ed. Further research should be conducted using established data sets to validate the methodology, and to address potential limitations, e.g. unobserved differences between treatment groups, and potential benefi ts of treatment in patients classifi ed as non-responders. OBJECTIVES: While randomized control trials (RCT) are the gold standard for drug approval, there is often a lack of data directly comparing different treatment options. An indirect comparison of the treatment effects may serve as a proxy for a head-tohead RCT, however, naively comparing treatments using published trial data without adjusting for distribution differences in patient characteristics and prognostic factors can result in misleading conclusions. a novel matched-adjusted approach to indirectly compare absolute survival estimates (median overall survival (OS) or progression free survival (PFS)) for competitive treatment options is presented. METHODS: This proposed approach requires patient-level data for one of the treatments and summary data of patient characteristics and survival outcomes for the comparator of interest. Using this proposed method, the researcher would fi rst decide on one or two matching variables that are prognostic for survival, and apply a program involving an extension of a common SAS 9.2 procedure, Proc Surveyselect, to select 1000 random repeated sub-samples from the original population with the same distribution of matched variables. The analysis also requires programming statements using ODS and survival analysis procedures. The median OS or PFS estimates are computed for each bootstrapped sample and a 95% confi dence interval (CI) is inferred around the mean of the sampled survival estimates. These absolute survival estimates, based on the adjusted population, can then be compared to the absolute survival estimates reported in published literature of the comparator treatment. CONCLUSIONS: In the absence of head-to-head RCT data, an adjusted indirect comparison accounts for observed differences between populations making them more comparable and results in an effect of treatment exposure on survival outcomes that is less likely due to confounders. OBJECTIVES: The objectives of this study are: 1) to systematically review the methods used in developing cost estimates in the recent German health economic literature; and 2) to examine the methodological approaches in terms of analytical framework, cost components, resource use and cost data sources in light of the national Institute for Quality and Effi ciency in Healthcare guidelines. METHODS: The MEDLINE database was searched for studies published between 1-Jan-2006 and 31-Dec-2008 estimating direct and/or indirect costs of health care interventions in Germany. Detailed information on the perspective of the analysis, time horizon, resource use categories, costing approach, valuation of resource use, resource use and unit cost/ price data sources were systematically collected. RESULTS: The literature search returned citations to 122 articles, of which 47 met the inclusion/exclusion criteria. Nearly half of the selected articles (23) adopted the societal perspective and 21 (44.7%) the perspective of German Statutory Health Insurance funds. In nearly three quarters of the studies (35) the time-horizon of the base-case analysis was no longer than one year. Direct medical costs were reported in almost all articles; 25 studies (53.2%) assessed only this cost category. Among the most common unit cost sources of health care services were reimbursement fees for outpatient and hospital services, together with market prices for drugs and medical devices, mentioned in 43 (91.5%) and 39 (83.0%) articles, respectively. CONCLUSIONS: Although the variability in the studies reviewed was very high, some common features emerged. Firstly, most cost estimates focus on direct medical costs only. Secondly, a comprehensive list or at least an exhaustive discussion of the relevant resource use is usually missing. Finally, the time-horizon is often too short to capture all relevant cost drivers and the assessment of the medical resource use not always consistent with the perspective of the analysis. OBJECTIVES: Economic analyses that take a societal perspective need to incorporate estimates of lost productivity due to premature death. Such estimates are likely to vary substantially across countries, making it a challenge to assess the value of alternative medical interventions on a global basis. Our goal was to develop a generic, web-based software tool based on rigorous analytic methods that would enable researchers to assess the expected discounted present value of lost productivity for persons who die prematurely at various ages in selected developed and emerging nations. METHODS: An analytic model framework was developed to estimate the expected discounted present value of lost productivity due to premature mortality from a societal perspective using a human capital approach (with value attached to household work, as data permitted). Key model inputs included life tables, labor force participation rates, wages, and discount rates. Default input parameter values were based on each country's national statistics, as available, or via generic "global" estimates when such data were lacking. RESULTS: Model results were generated for 20 countries around the world, and varied substantially based on patient age at death and the economic region in which a country is located. For illustration purposes, the discounted present values of lost productivity for a person who dies at age 25-29 in the US, Brazil, and Sweden were estimated to be $US 945,162, 124,795, and 805,740, while the corresponding values for those who die at age 45-49 were 622,248, 76,976, and 480,480. The webbased interface allows researchers to select the country of interest, modify default values, and conduct sensitivity analyses. CONCLUSIONS: This generic web-based software tool allows researchers to easily incorporate the value of lost productivity due to premature mortality into economic analyses that take a societal perspective, and provides estimates for many different developed and emerging countries. OBJECTIVES: The inclusion of loss productivity costs in pharmacoeconomic studies is still a subject of considerable debate. The aim of this study was to quantify the work impairment due to general health status in Poland with the Productivity and Activity Impairment: General Health (WPAI-GH) Questionnaire. METHODS: Data were obtained from a survey that incorporated the WPAI-GH questionnaire and information on burden of care for a sick family member during computer-assisted personal interview in a representative sample of the Polish general population aged more than 15 years. There were 2019 respondents in total, gathered in two waves in January and May 2010. RESULTS: The total population comprised 795 subjects in paid jobs. Subjects reported 4.5% work time missed (absenteeism) during the past 7 days. Impairment while at work (presenteeism) amounted to 13.9% of total time. The overall work productivity loss (absenteeism plus presenteeism) equalled 15.2%. Impairment in performing daily activity was 15.6% in the past 7 days. Observed percentages were in general higher in subject from the fi rst wave of study (January 2010) than from second wave (May 2010)-differences did not reach statistical signifi cance. The general tendency of a higher absenteeism and a lower presenteeism values among men than among women were observed. CONCLUSIONS: Productivity and Activity Impairment measured by WPAI-GH in the Polish population are similar to these observed in other European countries and the U.S. Moderate differences between values estimated in January and May suggest limited impact of seasonal diseases such as infl uenza on productivity. OBJECTIVES: There exists no standardised list of unit costs (UC) for use in economic evaluations in Spain. Tariffs published by the 17 Autonomous Communities (ACs) are often used as a proxy for costs. We explored the structure and contents of AC tariff lists and tariff ranges for common resource use items. METHODS: Current tariff lists published in the Offi cial Bulletins from 16 Spanish ACs were retrieved. Tariffs for key health services in the following categories were extracted: specialist and A&E visits, hospitalization, investigations, procedures, laboratory tests, and episodes of care (DRGs). We qualitatively assessed structure and contents of tariff lists, item content for selected items. Ranges, normal mean and weighted mean (according to
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PMC3 A NOVEL APPROACH TO MATCHING ADJUSTED INDIRECT COMPARISON ANALYSIS USING COMMON SAS 9.2 PROCEDURES
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PMC4 COST ESTIMATION IN HEALTH ECONOMIC EVALUATIONS IN GERMANY: A SYSTEMATIC REVIEW
Merito M, Breitscheidel L, Eichmann F Kendle GmbH, Munich, Germany OBJECTIVES: The objectives of this study are: 1) to systematically review the methods used in developing cost estimates in the recent German health economic literature; and 2) to examine the methodological approaches in terms of analytical framework, cost components, resource use and cost data sources in light of the national Institute for Quality and Effi ciency in Healthcare guidelines. METHODS: The MEDLINE database was searched for studies published between 1-Jan-2006 and 31-Dec-2008 estimating direct and/or indirect costs of health care interventions in Germany. Detailed information on the perspective of the analysis, time horizon, resource use categories, costing approach, valuation of resource use, resource use and unit cost/ price data sources were systematically collected. RESULTS: The literature search returned citations to 122 articles, of which 47 met the inclusion/exclusion criteria. Nearly half of the selected articles (23) adopted the societal perspective and 21 (44.7%) the perspective of German Statutory Health Insurance funds. In nearly three quarters of the studies (35) the time-horizon of the base-case analysis was no longer than one year. Direct medical costs were reported in almost all articles; 25 studies (53.2%) assessed only this cost category. Among the most common unit cost sources of health care services were reimbursement fees for outpatient and hospital services, together with market prices for drugs and medical devices, mentioned in 43 (91.5%) and 39 (83.0%) articles, respectively. CONCLUSIONS: Although the variability in the studies reviewed was very high, some common features emerged. Firstly, most cost estimates focus on direct medical costs only. Secondly, a comprehensive list or at least an exhaustive discussion of the relevant resource use is usually missing. Finally, the time-horizon is often too short to capture all relevant cost drivers and the assessment of the medical resource use not always consistent with the perspective of the analysis.
PMC5
DEVELOPMENT OF A WEB-BASED SOFTWARE TOOL TO EVALUATE THE ECONOMIC IMPACT OF LOST PRODUCTIVITY DUE TO PREMATURE MORTALITY IN DEVELOPED AND EMERGING NATIONS
Marton JP 2 , Menzin JA 1 , Willke RJ 2 1 Boston Health Economics, Inc., Waltham, MA, USA; 2 Pfi zer, Inc, New York, NY, USA OBJECTIVES: Economic analyses that take a societal perspective need to incorporate estimates of lost productivity due to premature death. Such estimates are likely to vary substantially across countries, making it a challenge to assess the value of alternative medical interventions on a global basis. Our goal was to develop a generic, web-based software tool based on rigorous analytic methods that would enable researchers to assess the expected discounted present value of lost productivity for persons who die prematurely at various ages in selected developed and emerging nations. METHODS: An analytic model framework was developed to estimate the expected discounted present value of lost productivity due to premature mortality from a societal perspective using a human capital approach (with value attached to household work, as data permitted). Key model inputs included life tables, labor force participation rates, wages, and discount rates. Default input parameter values were based on each country's national statistics, as available, or via generic "global" estimates when such data were lacking. RESULTS: Model results were generated for 20 countries around the world, and varied substantially based on patient age at death and the economic region in which a country is located. For illustration purposes, the discounted present values of lost productivity for a person who dies at age 25-29 in the US, Brazil, and Sweden were estimated to be $US 945,162, 124,795, and 805,740 , while the corresponding values for those who die at age 45-49 were 622,248, 76,976, and 480,480. The webbased interface allows researchers to select the country of interest, modify default values, and conduct sensitivity analyses. CONCLUSIONS: This generic web-based software tool allows researchers to easily incorporate the value of lost productivity due to premature mortality into economic analyses that take a societal perspective, and provides estimates for many different developed and emerging countries.
PMC6 ASSESSING PRODUCTIVITY AND ACTIVITY IMPAIRMENT DUE TO ILLNESS IN POLAND
Wrona W, Hermanowski T, Jakubczyk M, Golicki D, Macioch T Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland OBJECTIVES: The inclusion of loss productivity costs in pharmacoeconomic studies is still a subject of considerable debate. The aim of this study was to quantify the work impairment due to general health status in Poland with the Productivity and Activity Impairment: General Health (WPAI-GH) Questionnaire. METHODS: Data were obtained from a survey that incorporated the WPAI-GH questionnaire and information on burden of care for a sick family member during computer-assisted personal interview in a representative sample of the Polish general population aged more than 15 years. There were 2019 respondents in total, gathered in two waves in January and May 2010. RESULTS: The total population comprised 795 subjects in paid jobs. Subjects reported 4.5% work time missed (absenteeism) during the past 7 days. Impairment while at work (presenteeism) amounted to 13.9% of total time. The overall work productivity loss (absenteeism plus presenteeism) equalled 15.2%. Impairment in performing daily activity was 15.6% in the past 7 days. Observed percentages were in general higher in subject from the fi rst wave of study (January 2010) than from second wave (May 2010)-differences did not reach statistical signifi cance. The general tendency of a higher absenteeism and a lower presenteeism values among men than among women were observed. CONCLUSIONS: Productivity and Activity Impairment measured by WPAI-GH in the Polish population are similar to these observed in other European countries and the U.S. Moderate differences between values estimated in January and May suggest limited impact of seasonal diseases such as infl uenza on productivity.
PMC7 TARIFF LISTS FROM SPANISH AUTONOMOUS COMMUNITIES: AN ASSESSMENT OF ITS STRUCTURE, CONTENTS, AND TARIFF LEVELS
De Cock E 1 , Raluy M 2 , Rovira J 3 1 United BioSource Corporation, Barcelona, Spain; 2 United BioSource Corporation, London, UK; 3 Barcelona, Spain OBJECTIVES: There exists no standardised list of unit costs (UC) for use in economic evaluations in Spain. Tariffs published by the 17 Autonomous Communities (ACs) are often used as a proxy for costs. We explored the structure and contents of AC tariff lists and tariff ranges for common resource use items. METHODS: Current tariff lists published in the Offi cial Bulletins from 16 Spanish ACs were retrieved. Tariffs for key health services in the following categories were extracted: specialist and A&E visits, hospitalization, investigations, procedures, laboratory tests, and episodes of care (DRGs). We qualitatively assessed structure and contents of tariff lists, item content for selected items. Ranges, normal mean and weighted mean (according to demographic size of ACs) were calculated for selected tariffs. RESULTS: We observed lack of consistency in structure and contents of tariff lists and in tariff levels, as exemplifi ed by: different categorization of services; incomplete listing of services; different terminologies; different levels of detail for common services (e.g. MRI: 2-127 options by body area and/or complexity); wide ranges of tariffs for most items (e.g. specialist visit: c56-c191, general ward per diem: c82-c569, simple MRI: c120-c634). Wide variations were also observed for other diagnostic investigations, (non-)surgical procedures, laboratory tests and DRGs. CONCLUSIONS: Wide ranges in tariffs for health resources commonly used in economic evaluations were identifi ed across ACs, with a difference between minimum and maximum values of at least factor 2. There exists no evidence on how tariffs are calculated and if they refl ect real cost. Available AC tariffs should be used with caution and a simple or weighted average across AC tariff lists may be used as proxies for nation-wide costs. Elaboration of a nation-wide list would avoid possible bias from analysts in the selection of cost values to obtain given results.
PMC8
BURDEN OF DISEASE AND ECONOMIC EVALUATION: ARE WE INVESTIGATING WHAT IT REALLY MATTERS?
Catalá-López F 1 , Garcia-Altés A 2 , Álvarez-Martín E 3 , Gènova-Maleras R 4 , Morant-Ginestar C 4 , Parada A 5 1 Spanish Medicines and Healthcare Products Agency (AEMPS), Madrid, Spain; 2 King's College London, London, UK; 3 Rey Juan Carlos University, Madrid, Spain; 4 Regional Health Council of Madrid, Madrid, Spain; 5 Agencia de Evaluación de Tecnología e Investigación Médicas (AATRM), Barcelona, Spain OBJECTIVES: We examined the association between economic evaluation studies performed in Spain in 1983-2008 and the burden of disease in the population. METHODS: Cross-sectional observational study. Electronic databases (Pubmed/ MEDLINE, SCOPUS, ISI Web of Knowledge, CRD, IME, IBECS) and reports from public agencies were systematically reviewed. Inclusion and exclusion criteria and a set of variables were defi ned to analyze the characteristics of the papers selected. Using the Global Burden of Disease (GBD) study classifi cation the following measures were calculated: years of life lost (YLLs), years lived with disability (YLDs), disabilityadjusted life-years (DALYs), and mortality by cause. Correlation and linear regression models were used. RESULTS: Cardiovascular diseases (15.7%), infectious and parasitic diseases (15.3%), and malignant neoplasms (13.2%) were the conditions most commonly addressed. Accidents and injuries, congenital anomalies, oral conditions, nutritional defi ciencies and other neoplasms were the categories with a lowest number of studies (0.6% from the total for each of them). The disease sub-categories most prevalent in the studies were lower respiratory infections (5.7%), ischemic heart disease (5.7%), hepatitis B and C (3.3%) and HIV/AIDS (3.1%). For GBD categories (n = 20), a correlation was seen with: mortality 0.67 (p = 0.001), DALYs 0.63 (p = 0.003), YLLs 0.54 (p = 0.014), and YLDs 0.51 (p = 0.018). By diseases sub-categories (n = 51), the correlations were low and non statistically signifi cant. CONCLUSIONS: There is a mild-moderate association of economic evaluations with the main causes of burden of disease. For some conditions, the data show over or under-representation of studies related to their burden generated. The burden of disease is a criterion that, in combination with effi ciency and equity, would allow to set recommendations to guide debates on health research priority setting.
PMC9
A NEO-RICARDIAN APPROACH TOWARD DISCOUNTING Parouty M, Boersma C, Postma MJ University of Groningen, Groningen, The Netherlands BACKGROUND: The major focus of the history of economic thought has been devoted to defi ning a scientifi c theory of value. An even harder task entails formulating a theory of intertemporal value. Work on this theory date back to the birth of modern economic thought. For example, some authors have argued that an intertemporal utility based theory of value involves the explanation of a quantity which can be directly observed and measured in terms of a quantity which cannot. Major current debates on discounting therefore surround the need for a scientifi c defi nition and the ethics towards intergenerational justice. OBJECTIVES: We investigate how several current issues in discounting might be irrelevant by adopting a Neo-Ricardian view of intertemporal value by recursively applying valuation of a commodity from value of input commodities, thereby simplifying to the Physiocratic School. We further investigate how our empirical model might be extended to current utilitarian philosophy. METHODS: We adopt a Sraffi an approach and devise a pure value-growth matrix that relies only on empirical data. We fi rst derive a 2 × 2 matrix and then a 3 × 3 matrix. We use health effects, income and a third externality for the derivations. RESULTS: It seems that the Neo-Riccardian approach provides the necessary requirements towards satisfying a scientifi c defi nition of intertemporal value and allows extension of the classical framework of health and wealth with a 3 rd dimension of externalities. Furthermore, by redefi ning the pure growth term in our 2 × 2 matrix with the Ramsey discount rate, our results simplify to current economic theory. CONCLUSIONS: Although modern economic theory explains value from a utilitarian viewpoint, it seems that it lacks robustness in explaining intertemporal value. Therefore, we suggest that the Sraffi an School of economic thought should also be considered when attempting to formulate a discount rate for health effects, within a concept of sustainable growth.
PMC10
RELIABILITY OF MANUFACTURERS' BUDGET IMPACT ESTIMATES IN POLAND
Iwanczuk T, Szewczyk K, Zagorska A Agency for Health Technology Assessment in Poland, Warszawa, Poland OBJECTIVE: To verify the reliability of the methodology used in the manufacturers' Budget Impact Analyses (BIAs) submitted in reimbursement dossier to Polish HTA Agency, we compared public payer (National Health Fund-NHF) actual expenditures on selected drugs with their estimated costs. METHODS: BIAs of medicines reimbursed for at least one year and assessed previously in Agency were selected for the analysis. The BI estimated by the manufacturer in the fi rst year after product's introduction to reimbursement was used. Estimated size of target population was compared with the actual one. The actual data was obtained from the NHF. BIAs for selected medicines were critically appraised to determine any variables that may have affected its reliability. RESULTS: 20 BIAs met inclusion criteria and were included into the study. Forty-fi ve percent (9/20) of the BI expenditures were underestimated. Median and mean difference between actual and estimated expenditure were 17,22% and 30,25% respectively. The overestimation was found in 55% BIAs (11/20); median = 262,26%, mean difference = 2267,25%. Population size was underestimated in 65% (13/20) of the BIAs. Median and mean difference between actual and estimated population were 25,61% and 33,93% respectively. Overestimation of the population was found in 35% (7/20) of the BIAs; median = 566,67%, mean difference = 573,28%. The main factors that could infl uence differences between predictions and actual spending were: underestimated (65%) or overestimated (35%) number of patients eligible for treatment, overestimated (30%) or underestimated (25%) market share, wrong assumption on 100% compliance (15%). CONCLUSION: The study has demonstrated large variances between predicted budget impact and actual expenditures on drugs. It also revealed signifi cant weaknesses in the quality of submitted BIAs, e.g.: errors in calculations, very limited data provided by manufacturer that unable to complete revision and reproduce of fi gures in the calculation.
PMC11 ARE THRESHOLD RANGES FOR COST PER QALY A BARRIER TO RESEARCH FOR LIFE EXTENDING TREATMENTS
Roberts G, de Nigris E Double Helix Consulting Group, London, UK As they are currently used thresholds for cost per QALY may provide a disincentive for companies to invest in research for therapies that prolong life in conditions with an already high treatment cost. Cost per QALY thresholds, although not the sole basis for decision making are a major infl uence on whether a technology is considered cost-effective by NICE. Discussions have centred on the most appropriate threshold level and how its value should be determined. However a consequence of cost per QALY thresholds that is not discussed is the impact they may have on future health care research. The cost per QALY for renal dialysis has been estimated at £30,000 1 , the higher end of what NICE considers acceptable. We have therefore reached the ceiling for the cost of treating renal disease. Assuming that utility is not improved a treatment that extends life will be at additional cost and have a cost per QALY greater than £30,000. Manufacturers of health care technologies may consider that the risk of not getting a product approved on cost-effectiveness grounds is not worth the fi nancial investment in its development. As health care costs continue to grow the management costs of more conditions will exceed £20,000 per year and future research may be stifl ed as manufacturers seek to develop products that replace rather than add to current treatments. Since the background treatment cost would cancel out in an incremental analysis a treatment could be more cost-effective than the one it replaces but perversely can still be at an increased cost which raises the cost per QALY of standard treatment above £20,000 or £30,000. As treatment costs for more conditions increase to threshold values (even if they are raised) manufactures may be advised to consider realigning their portfolio and investment to other diseases.
PMC12
ASSESSMENT OF THE WORKLOAD REAL TIME DEDICATED TO EACH PATIENT IN INTENSIVE CARE UNITS (ICU): PRELIMINARY RESULTS OF THE CRRÉA STUDY
Garrigues B 1 , Lefrant JY 2 , Pribil C 3 , Bazin J 4 , Maurel F 5 1 Centre Hospitalier du pays d'Aix, Aix-en-Provence, France; 2 CHU de Nimes, Nimes, France; 3 GSK France, Marly le roi, France; 4 CHRU de Clermont-Ferrand, Clermont-Ferrand, France; 5 IMS Health, Puteaux, France OBJECTIVES: The objective of the CRRéa study is to assess the real daily cost of a patient's stay in ICU in France. We present here preliminary results regarding the average time spent per patient by different health caregivers. METHODS: A prospective multicentric health economic study was performed in 23 ICUs of different French hospitals randomly selected from the PMSI database (French National Hospital database). In a one day study, 5 adult patients were randomly selected among patients with a simplifi ed severity score ≥ 15 in each ICU. Data on all the resources used, treatments administered, biological tests performed, etc. and time spent by different health caregiver to take care of each patient over a 24 hour period (direct and indirect interventions) were collected through a time and motion analysis method involving the professionals themselves. RESULTS: A total of 109 patients (median age = 66 years, 65% males) of 22 intensive care units (15 polyvalent, 3 surgical and 4 medical ICUs) were included. 104 of them were followed over 24 hours (there were 2 deaths and 3 early withdrawals). On the day of the study, 84% of patients were mechanically
